Malignant Melanoma Archive | IOZK

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

2020-02-07/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)

Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines

2020-01-31/in Dendritic Cells, Malignant Melanoma /von 2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

2020-01-24/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488

Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors

2019-10-09/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-09 / Front Immunol 2019;10:2353

Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects

2019-08-17/in Hyperthermia, International Publications, Malignant Melanoma /von 2019-08-17 / Int J Mol Sci 2019 Aug;20(16)

A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.

2019-06-03/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)

Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.

2019-05-31/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)

Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.

2019-05-31/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)

STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells

2019-05-29/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2019-05-29 / Front Oncol 2019;9:436

Melanoma vaccines: clinical status and immune endpoints

2019-04-01/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118